Inventiva announced publication in the peer-reviewed medical journal Clinical Gastroenterology and Hepatology, of its analysis on new non-invasive biomarker signatures predictive of histology response following treatment with lanifibranor (pan-PPAR agonist) in patients with MASH and fibrosis. While there are multiple diagnostic scores currently available, we are encouraged to learn that Inventiva's test suggested better predictive accuracy than existing options including FIB4. With recruitment i...
A director at UCB SA bought 674 shares at 138.350EUR and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing ...
Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor ► Biomarker signatures were developed to predict histological treatment response to lanifibranor treatment in patients with MASH and fibrosis ► The biomarker signatures developed for fibrosis improvement, MASH resolution and composite histological endpoints, suggested better predictive accuracy than other diagnostic scores available including FIB4, FIBC3, ABC3D, NFS, ELF and MACK-3 ► ...
Inventiva annonce la publication dans Clinical Gastroenterology and Hepatology de l’analyse de nouvelles signatures de biomarqueurs prédictives de la réponse histologique chez les patients atteints de MASH traités par lanifibranor ► Des signatures de biomarqueurs ont été développées pour prédire la réponse histologique au traitement par lanifibranor chez les patients atteints de MASH avec fibrose ► Les signatures de biomarqueurs développées pour l’amélioration de la fibrose, la résolution de la MASH et les critères histologiques composites, ont suggéré une meilleure prédictivité que les ...
ASM will report its 1Q25 results on Tuesday, 29 April after the market close. We believe that results will remain strong despite the sector wide uncertainty. ASM's key driver is the shift to GAA, which we expect to remain strong. We expect that ASM will continue to strongly outperform the sector. We reiterate our BUY rating but lower our target price to €750 per share (from €800). ASM International is on the ING Benelux Favourites list.
Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F Daix (France), New York City (New York, United States), April 15, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced that it had filed its 2024 Universal Registration Document for the year ended December ...
Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2024 et de son Rapport Annuel 2024 (« Form 20-F ») Daix (France), New York City (New York, États-Unis), le 15 avril 2025 - Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH ») et d'autres maladies avec un besoin médical non satisfait, annonce aujourd’hui avoir déposé son Document d’Enreg...
In this sector note we take a close look at the semiconductor universe and go over end market dynamics, semi manufacturing trends and the impact on the WFE market. We provide detailed overviews of historical market trends and short term adjustments. We show that lower demand from China is a real risk for the WFE market, as we don't expect the non-China WFE revenues will increase with 28% y/y in 2025, which CSS implies. Our analysis shows a clear 10% risk on WFE estimates based on fundamentals, e...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.